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Abstract
Background: Molecular heterogeneity of colorectal carcinoma (CRC) is well recognized, forming the rationale for 
molecular tests required before administration of some of the novel targeted therapies that now are rapidly entering 
the clinics. For clinical research at least, but possibly even for future individualized tumor treatment on a routine basis, 
propagation of patients' CRC tissue may be highly desirable for detailed molecular, biochemical or functional analyses. 
However, complex logistics requiring close liaison between surgery, pathology, laboratory researchers and animal care 
facilities are a major drawback in this. We here describe and evaluate a very simple cryopreservation procedure for 
colorectal carcinoma tissue prior to xenografting that will considerably reduce this logistic complexity.
Methods: Fourty-eight CRC collected ad hoc were xenografted subcutaneously into immunodeficient mice either 
fresh from surgery (N = 23) or after cryopreservation (N = 31; up to 643 days).
Results: Take rates after cryopreservation were satisfactory (71%) though somewhat lower than with tumor tissues 
fresh from surgery (74%), but this difference was not statistically significant. Re-transplantation of cryopreserved 
established xenografts (N = 11) was always successful. Of note, in this series, all of the major molecular types of CRC 
were xenografted successfully, even after cryopreservation.
Conclusions: Our procedure facilitates collection, long-time storage and propagation of clinical CRC specimens (even 
from different centres) for (pre)clinical studies of novel therapies or for basic research.
Background
The last decade has witnessed a tremendous progress in
understanding the molecular pathology and the patho-
genesis of colorectal carcinoma (CRC). Chromosomal as
well as microsatellite instability and the CpG island meth-
ylator phenotype have been defined as major molecular
pathogenetic mechanisms, giving rise to the main molec-
ular classes of CRC [1,2]; and genome wide mutational
analysis have shown that per individual cancer a limited
number of signal transduction pathways are dysregulated
by "driver" mutations in some (typically about 15) from a
set of about 80 so-called candidate cancer genes [3,4].
In the wake of this, targeted therapies for CRC are
beginning to enter the clinics, EGF-receptor blockade
(with the pre-requisite of K-Ras mutational analysis)
being the first already to be used more generally among
these [5,6]. It may be expected for the near future that
patient's tumor tissues, besides being subject to tradi-
tional histopathological examination, will be used for var-
ious additional molecular testings. While some of these
can be done with conventional paraffin-embedded mate-
rial, some will require frozen tumor tissue. But, conceiv-
ably, more elaborate molecular analyses or even
functional tests eventually may be desirable, and for these
analyses at least xenograft tumors may be prime choice
[7-9].
However, xenografting as a routine will pose consider-
able logistical difficulties as technical expertise of differ-
ent fields (surgery, pathology, molecular biology and
animal care) must be brought together. Clearly, separat-
ing location and occasion when the tumor specimen
accrues, the molecular analyses are done, and the
engraftings are performed would rigorously reduce this
logistical complexity. In addition, at least for research
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purposes, it would allow preselection of tumor specimens
with desired molecular features in advance of the techni-
cally demanding xenografting procedures.
We here report an easy and effective method to store
CRC tissue by cryopreservation for use in xenografting at
a later date. Specifically, we aimed to explore feasibility
and success rate in a consecutive series of CRCs collected
ad hoc, comparing xenografting of tumor tissue fresh
from surgery with xenografting after cryopreservation. In
addition, we demonstrate that cryopreservation of estab-
lished xenograft tumors for re-xenografting is also feasi-
ble. And finally, we show that a balanced distribution of
the different molecular classes of CRCs will be obtained.
Methods
Tumor specimen collection and cryopreservation
Resection specimens of primary tumors (N = 48; primary
CRCs without previous chemo-or radiotherapy) were
received fresh from surgery. Tumor tissue cubes (ca. 3 × 3
× 3 mm) were cut from the deep invasive parts with a
sterile scalpel blade.
Mirror blocks for cryostat sections were prepared from
the adjacent parts of the tumours. Alternatively, xeno-
graft tumors were removed under sterile conditions and
pieces were taken from the peripheral parts of the
tumors. Again, adjacent tumour tissues were used for
cryostat sections. Typically, 4 tumor pieces were trans-
ferred into sterile cryo-tubes (greiner-bio-one, Fricken-
hausen, Germany) in 1.5 ml freezing medium (foetal calf
serum containing 10% DMSO), sealed in a Freezing Con-
tainer (Nalgene, Rochester, NY, USA), and placed imme-
diately at -80°C. Until transplantation tubes were kept at -
80°C (for a maximum of 6 weeks) or, after overnight cool-
ing, transferred into liquid nitrogen (for longer storage
periods). For xenografting, cryopreserved tumor pieces
were thawed at 37°C. Prior informed consent was
obtained in written from all patients, and all procedures
were approved by the Ethics Committee of the University
of Rostock (reference number II HV 43/2004) in accor-
dance with generally accepted guidelines for the use of
human material.
Tumor xenografting
Tumor xenograftings were done by one of the following
approaches: (I) xenografting of primaries on the day of
surgery (n = 23); (II) xenografting of primaries after cryo-
preservation (n = 31); and (III) re-transplantation of
xenografts after cryopreservation (n = 11). Tumor pieces
were implanted subcutaneously uni-or bilaterally into the
flanks of six to eight week old female mice under ether
anaesthesia for a short period of time. We used NOD-
SCID (NOD.CB17-Prkdcscid/J in cases of HROC24 to
HROC46 and nude mice (NMRI nu/nu) for the subse-
quent xenograftings. As assessed by cryostat sections
from the mirror blocks, there was seen an area fraction of
30 - 80% of viable tumour in the tissues used for xeno-
grafting. The numbers of mice receiving grafts and the
numbers of grafts for each animal are given for each indi-
vidual tumor in Table 1. Mice were kept in the animal
facilities of the medical faculty of the University of Ros-
tock and maintained in specified pathogen-free condi-
tions. Animals were exposed to 12-h light/12-h darkness
cycles and standard food and water including antibiotics
(Co-trimoxazol) ad libitum. Their care and housing were
in accordance with guidelines as put forth by the German
Ethical Committee and the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal
Resources, National Research Council; NIH Guide,
vol.25, no.28, 1996). Growth of tumours to volumes of 1 -
1.5 cm3 was taken as evidence of successful xenografting,
and the animals were then sacrificed for collection of
tumour tissues for further studies.
Morphological and molecular studies
Dissections and histopathological examination of the pri-
mary tumors were done according to standard protocols
for surgical pathology reports of CRCs [10], and addi-
tional staging information was compiled from patients'
clinical charts. Primary tumors and xenografts were
embedded in paraffin, and 4 μm H&E sections were
o b t a i n e d  a s  w e l l  a s  β - c a t e n i n  a n d  M L H 1  a n d  M S H 2
immunostainings.
The molecular analyses were done as previously pub-
lished in detail [2]. Briefly, the Bethesda panel of micro-
satellite markers was used to test for microsatellite
instability, chromosomal instability was assessed by
DNA-flow cytometry and LOH analyses with various
dinucleotide markers (D5S1385, D5S346 (5q21);
D8S1734, D8S1771, NEFL (8p21); D9S942, D9S1748
(9p21); D17S1832, D17S250 (17p23); D18S70 (18q23)),
and mutation analyses of the APC gene as well as the K-
Ras and B-Raf genes were done. Finally, DNA-methyla-
tion was assessed by the MethyLight technology with the
marker panel originally published by Ogino et al. and
m o d i f i e d  b y  u s  [ 2 ] .  B a s e d  o n  t h e s e  m o l e c u l a r  d a t a ,
tumors in this series were classified as sporadic standard
type CRC (spStdCRC), sporadic high-degree microsatel-
lite instable CRC (spMSI-H), hereditary non-polyposis
CRC-type (HNPCC-type), or CpG island methylator phe-
notype CRC (CIMP-type).
Verification of human origin of the xenograft tumors
A human specific PCR was performed by amplification of
a portion of the human mitochondrial cytochrome b gene
as previously described [11]. Briefly, the reaction mixture
(25 μl) contained 25 ng of gDNA, 0.1 mM of each primer
(L15674: TAGCAATAATCCCCATCCTCCATATAT,
H15782: ACTTGTCCAATGATGGTAAAAGG), 200 μMLinnebacher et al. BMC Cancer 2010, 10:362
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Table 1: Details of xenograftings and outcomes.
Tumor-ID Fresh Cryopreserved Days frozen
HROC24 M1(+); M2(-); M3*
HROC26 M1(-); M2(-); M3(-)
HROC29 M1(+); M2(+); M3(-)
HROC32 M2(+); M1*
HROC33 M1(-); M2(-); M3(-)
HROC37 M1(-); M2(-)
HROC38 M1(-); M2(-)
HROC39 M1(+); M2(+)
HROC40 M1(+); M2(+)
HROC45 M1(-); M2(-)
HROC46 M1(+); M2(+)
HROC48 M1(-;-); M2(-;-);M3(+;+); M4(+;-) 161/643
HROC50 M1(+;+); M2(-;+) 120
HROC51 M1(-;-); M2(-;-) 117
HROC52 M1(-;-); M2(-;-) 94
HROC53 M1(-;+); M2(-;-) 84
HROC54 M1(-;-); M2(-;+) 64
HROC55 M1(-;-); M2(-;-);M3(-;+); M4(-;-) 6/489
HROC56 M1(-); M2(-)
HROC57 M1(+); M2(-)
HROC59 M1(+;+); M2(-;+)
HROC60 M1(-;+); M2(-;-)
HROC61 M1(-;-); M2(-;-) 58
HROC62 M1(-;-); M2(+;-) 51Linnebacher et al. BMC Cancer 2010, 10:362
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HROC63 M1(-;+); M2(-;-) M1(-;-); M2(-;-) 88
HROC64 M1(+;-); M2(-;-) 78
HROC65 M1(+;-); M2(-;-) M1(+;-); M2(-;-) 13
HROC66 M1(-;-); M2(-;-) 47
HROC67 M1(-;-); M2(-;-) 42
HROC68 M1(+;+); M2(+;+) M1(-;+); M2(-;+) 38
HROC69 M1(+;+); M2(+;+) M1(-;-); M2(-;-) 28
HROC70 M1(-;-); M2(-;+) M1(-;+); M2(-;-) 27
HROC71 M1(+;+); M2(-;+) 27
HROC72 M1(+;+); M2(-;-) 240
HORC73 M1(-;-); M2(-;-) 238
HROC74 M1(+;+); M2(-;-) 230
HROC75 M1(-;+); M2(+;+) 223
HROC78 M1(+;+); M2(-;-) 188
HROC80 M1(-;+); M2(-;-) 119
HROC81 M1(-;-); M2(-;+) 118
HROC82 M1(+;+); M2(-;-) 118
HROC83 M1(-;-); M2(-;-) 87
HROC84 M1(-;+); M2(-;-) 73
HROC85 M1(-;+); M2(+;+)
HROC86 M1(-;+)
HROC87 M1(-;+); M2(-;+) 9
HROC88 M1(+;+); M2(-;+) 7
HROC89 M1(-;-); M2(+;-) M1(+;+) 103
M denotes mice xenografted, the outcome is given in parentheses as index + or index -. One index is given for uni-and two indices for bilateral 
xenografts. * animals died due to problems with anaesthesia. Underlined: repetition of the xenografting procedure.
Table 1: Details of xenograftings and outcomes. (Continued)Linnebacher et al. BMC Cancer 2010, 10:362
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dNTPs, 1 × standard reaction buffer and 0.1 U Taq DNA
polymerase (Bioron, Ludwigshafen, Germany). PCR was
performed in a standard thermal cycler for 40 cycles of 30
s at 96°C, 40 s at 59°C, and 1 min at 72°C. Products were
separated on a 1% agarose gel and results were scored
positive with the appearance of a band of 157 bp.
Statistics
All data were entered into a computerized data bank (Sta-
tistical Package for the Social Sciences, SPSS version
13.0). Testing for significance of cross-tabulated data was
done by two-sided Fisher's exact T-test. The criterion for
significance was taken to be p < 0.05.
Results
Overall, 48 primary CRCs were collected for these xeno-
grafting experiments. 47 were adenocarcinomas, and 1
tumor was a large cell neuroendocrine carcinoma (HROC
57). Information on histological and molecular types as
well as staging information and patient characteristics are
summarized in Table 2.
Xenografting of 23 tumors fresh from surgery was suc-
cessful in 17 cases (74% take). By comparison, 31 tumors
were xenografted after cryopreservation for 6 to 643 days,
and this was successful in 22 cases (71% take - summa-
rized in Table 2), Thus, there was not observed a statisti-
cally significant difference in the overall success rates
between fresh (n = 17/23) and cryopreserved (n = 22/31)
samples (p = 0.815, Fisher's exact T-test). As most ani-
mals received bilateral xenografts comparison between
total numbers of fresh and cryopreserved xenografts
could be made. Again, the difference was not statistically
significant although a trend to reduced success after cry-
opreservation was observed (n = 34/68; 50% fresh, n = 40/
130; 31% cryopreserved, p = 0,098; Table 1). In two cases,
where xenografts did not grow successfully after cryo-
preservation, enough frozen tumor pieces were left to
repeat xenografting at a much later date (643 and 489
d a y s ) ,  t h i s  t i m e  w i t h  s u c c e s s  ( a n i m a l s  M 3  a n d  M 4  o f
HROC48 and HROC55; Table 1, underlined).
For 6 of the 48 tumors, sufficient material was available
to attempt both xenografting of tumor tissue fresh from
surgery and xenografting of tumor tissues after cryo-
preservation (13 to 103 days). This was successful for all
the tumor tissues xenografted fresh from surgery, and for
4 cases of cryopreserved tissues (67%; Table 2). Details on
the xenograftings and their outcomes are given in Table 1.
Re-transplantation of xenograft tumors after cryo-
preservation was attempted for 11 tumors, and this could
be carried out successfully in all cases. These tumor tis-
sues were from passages 2 to 8 and had been cryopre-
served for 56 to 455 days (Table 3). In terms of grafts, 47
of 54 grafts were accepted (87%; Table 3).
As expected, histologically the xenograft tumors closely
resembled their primaries (Figure 1). PCR studies ampli-
fying part of the human mitochondrial cytochrome b
gene gave further proof of the human origin of these
tumors (data not shown). Furthermore, the molecular
analyses revealed that xenografting could be carried out
successfully for all the molecular types of CRC without
any evident bias. Specifically, xenografts were obtained
for 27 spStdCRC, 6 spMSI-H tumors, 2 HNPCC-type
tumors, and 3 CIMP tumors.
Generally, xenografting was well tolerated by the ani-
mals. No signs of superinfection or suppuration were
seen in any of the cases and consequently, no death from
infection occurred. This was even true for those cases
where tumor samples contained bacteria as judged from
infections observed in parallel cultures in vitro (data not
shown). In this series, we never observed metastases.
Discussion
In this study, we were able to show that tumor tissue from
primary CRC surgical resection specimens can be cryo-
preserved and successfully xenografted into mice even
after prolonged periods of storage (up to 643 days). Even
though take rates with this procedure seem to be lower
than with tumor tissue used fresh from surgery (71%
overall take for cryopreserved vs. 74% overall take for
fresh tissues), this difference was not of statistical signifi-
cance. Besides, it is still satisfactory and compares favour-
ably to xenograft take rates reported by other groups [12-
15]. Not unlikely, take rates could even be improved by
increasing the number of implantations or by Matrigel-
soaking of tumor pieces before xenografting as suggested
by Fujii et al. as well as by Sorio et al. [14,15]. The latter
group was also the first to report a successful cryopreser-
vation technique for pancreatic cancers [14]. As a techni-
cally very simple method, cryopreservation of CRC
tumor tissue prior to xenografting as reported here may
be quite appealing to both clinical and basic researchers
alike for the following reasons:
(1) Cryopreservation before xenografting considerably
reduces logistic constraints. If tumor tissue is xenografted
fresh from surgery the work-flow is very complex. At first
liaison will have to be made with the surgical colleagues
for the resection specimen to be brought to the pathology
department. From there the tumor tissue is handed over
to the xenograft-team, often past usual work-hours; and
presuming in any case that there are animals ready for use
in the breeding-facilities on the day of surgery. Obviously,
putting a break into this will make the procedure much
easier.
(2) Cryopreservation before xenografting facilitates col-
lection of large numbers of tumor specimens, even from
different centres. This may be important for pre-clinical
studies addressing e.g. the effects of targeted therapies asLinnebacher et al. BMC Cancer 2010, 10:362
http://www.biomedcentral.com/1471-2407/10/362
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Table 2: Data of colorectal carcinomas used for xenografting experiments and overall results of outcomes.
Tumor-ID Age/Gender Site* TNM-Stage Molecular type† Fresh Cryo
HROC24 98/m Right colon G2T2N0M0 spMSI Success ND‡
HROC26 60/m Left colon G3T4N2M1 spStd Failure ND
HROC29 59/m Right colon G3T3N2M1 HNPCC Success ND
HROC32 82/f Right colon G2T4N2M1 spStd Success ND
HROC33 70/f Left colon G2T3N1M0 spStd Failure ND
HROC37 77/m Right colon G3T2N0M0 ND Failure ND
HROC38 67/f Right colon G2T3N0M0 spStd Failure ND
HROC39 69/m Right colon G3T4N0M0 spStd Success ND
HROC40 69/m Left colon G3T3N1M0 CIMP-H Success ND
HROC45 52/m Right colon G3T4N0M0 ND Failure ND
HROC46 66/m Right colon G3T3N0M1 spStd Success ND
HROC48 68/m Right colon G3T2N1M0 spMSI ND Success
HROC50 67/f Right colon G2T4N0M0 spMSI ND Success
HROC51 70/m Left colon G3T4N2M1 spStd ND Failure
HROC52 55/f Left colon G2T2N0M0 spStd ND Failure
HROC53 72/f Right colon G3T3N0M0 spMSI ND Success
HROC54 63/f Left colon G2T3N2M0 spStd ND Success
HROC55 81/f Right colon G3T2N0M0 spMSI ND Success
HROC56 70/m Right colon G1T3N0M0 ND Failure ND
HROC57 43/m Right colon G3T3N2M1 NA§ Success ND
HROC59 76/m Right colon G2T3N1M1 spStd Success ND
HROC60 71/m Right colon G2T2N0M0 CIMP-H Success ND
HROC61 57/m Rektum G3T3N0M0 spStd ND Failure
HROC62 84/f Right colon G3T4N2M0 spStd ND SuccessLinnebacher et al. BMC Cancer 2010, 10:362
http://www.biomedcentral.com/1471-2407/10/362
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HROC63 81/f Left colon G2T4N0M0 spStd Success Failure
HROC64 71/m Left colon G2T2N0M0 spStd ND Success
HROC65 73/f Right colon G3T3N2M1 spStd Success Success
HROC66 75/m Rektum G2T3N2M0 spStd ND Failure
HROC67 54/m Left colon G2T3N1M0 spStd ND Failure
HROC68 84/m Left colon G2T4N2M0 spStd Success Success
HROC69 62/m Right colon G3T3N0M1 spStd Success Failure
HROC70 65/f Right colon G3T4N1M0 spStd Success Success
HROC71 52/m Right colon G2T3N0M0 HNPCC ND Success
HROC72 61/m Right colon G2T3N2M1 ND Success
HORC73 69/m Left colon G2T3N0M0 ND Failure
HROC74 80/m Left colon G2T4N0M0 spStd ND Success
HROC75 58/m Left colon G2T3N0M0 spStd ND Success
HROC78 75/m Right colon G3T3N0M0 CIMP-H ND Success
HROC80 72/m Right colon G2T3N2M1 ND Success
HROC81 21/f Right colon G3T4N0M1 spStd ND Success
HROC82 62/m Right colon G2T3N0M0 ND Success
HROC83 85/f Right colon G2T3N1M1 ND Failure
HROC84 88/f Left colon G2T3N0M0 spStd ND Success
HROC85 65/m Rektum G2T3N0M0 spStd Success ND
HROC86 79/f Left colon G2T3N1M0 spStd Success ND
HROC87 76/f Left colon G3T3N0M0 spMSI ND Success
HROC88 69/f Right colon G2T3N1M0 ND Success
HROC89 80/m Rektum G2T3N0M1 spStd Success Success
* Right colon (coecum to splenic flexure), left colon (descending colon and sigmoid), Rektum. † Abbreviations for molecular types of 
colorectal carcinomas. ‡ ND - not determined/not done. § NA - not applicable.
Table 2: Data of colorectal carcinomas used for xenografting experiments and overall results of outcomes. (Continued)L innebacher et al. BMC Cancer 2010, 10:362
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it has been shown that human tumor xenografts can be
used for prediction, especially when panels are used
[16,7-9]. Conceivably, even, cryopreservation could allow
post hoc analysis and propagation in xenografts of those
patients' tumor tissue that have responded (or not
responded) to specific therapies.
(3) Cryopreservation before xenografting allows prese-
lection of frozen tumor samples out of a larger collection.
This drastically reduces time and resources needed to
obtain individual xenografts of a desired molecular type.
Important to note in this respect is, apparantly by our
procedure none of the major molecular types of CRC
would be excluded.
(4) Finally, we observed that cryopreservation of estab-
lished xenografts of CRC samples for later re-transplanta-
tion is particularly successful (100% take in terms of cases
and 87% in terms of grafts). This may be interesting if
low-passage xenografts are desired, as it has been shown
that similar to cell lines xenografts may acquire additional
mutations and changes in the karyotype [17,12]; and it is
very convenient in relieving laboratories from the neces-
s i t y  o f  c o n t i n u o u s  p a s s a g i n g .  M o r e o v e r ,  i t  w i l l  g r e a t l y
facilitate the exchange of well-characterized models
between different institutions.
Conclusions
In the presented study we demonstrate the feasibility of
xenografting of clinical CRC specimens after a transient
cryopreservation step. A statistical comparison of the
Table 3: Successful re-xenografting after cryopreservation.
Tumor-ID Passage number Days frozen Success rate by grafts
HROC24 3 148 2/2
HROC29 6-8 147, 182, 189 7/10
HROC32 5 168 4/4
HROC39 2 164 4/4
HROC40 2 191 4/4
HROC46 2 455 7/8
HROC50 2, 3 120, 168 5/6
HROC53 2, 3 84, 168 6/6
HROC54 2 56 2/2
HROC59 2 119 2/2
HROC71 2 141 4/4
Figure 1 Tumor morphology. Examples of (a) primary tumor 
(HROC50) and (b) its xenograft. Compared to its primary, the tumor ar-
chitecture, growth pattern, and cytological features are well preserved 
in the xenograft tumor.
(a)
(b)Linnebacher et al. BMC Cancer 2010, 10:362
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success rates with and without cryopreservation revealed
no significant difference. In addition, we show that cryo-
preservation of established xenograft tumors for re-xeno-
grafting is particularly feasible. And finally, we show that
a balanced distribution of the different molecular classes
of colorectal carcinomas will be obtained using this pro-
cedure. These findings may have immediate impact on
the improvement of preclinical drug testing procedures.
To the best of our knowledge; this has never been done
for CRC.
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